Table 1

Demographic and clinical characteristics of patients with SLE at inclusion visit and during follow-up

N (%) or median (IQR)/mean±SD
Inclusion visit data
Number of patients348
Gender (female)323 (92.8)
Ethnicity (white)335 (96.3)
Age (years)45.1 (20.9); 45.2±14.6
Disease duration (years)2.1 (5.6); 4.2±6.5
Organ damage (SDI >0)95 (27.3)
PGA (0–3)2.0 (0.5); 1.8±0.5
≥2187 (53.7)
SLEDAI-2K8 (4); 8.5±4.8
≥1097 (27.9)
Clinical SLEDAI-2K6 (4); 7.0±4.3
≥6225 (64.7)
Follow-up data
Number of visits3492
Number of visits per patient10 (4); 10.0±3.4
Follow-up (patient-months)18 777
Follow-up, per patient (months)60 (27); 54±18
Time-adjusted variables (per patient)
SLEDAI-2K3.4 (3.0); 4.0±2.2
PGA0.84 (0.72); 0.90±0.47
Prednisone equivalent (mg/day)8.6 (23.8); 29.5±43.6
Remission (DORIS) attainment
At least once215 (61.8)
Number of visits (excluding inclusion visit)771 (24.5)
Number of visits in target per patient1 (4); 2.2±2.6
Cumulative target duration per patient (months)7.5 (25.0); 14.1±16.7
Low disease activity (LLDAS) attainment
At least once323 (92.8)
Number of visits (excluding inclusion visit)1575 (50.1)
Number of visits in target per patient4 (5); 4.5±2.9
Cumulative target duration per patient (months)27 (30); 27.5±18.0
  • DORIS, Definition of Remission in SLE; LLDAS, Lupus Low Disease Activity State; PGA, Physician Global Assessment; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000.